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of research on bipolar disorder is to be applauded, but fur-
ther research is needed: for bipolar disorder in general, and 
for bipolar depression and the long-term treatment specifi -
cally. Given the complexity of the disorder and the many clin-
ical uncertainties, eff ectiveness studies should be installed. 
 Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 Bipolar disorder has become a clinical and health-eco-
nomic challenge for the 21st century  [1] : a highly preva-
lent disorder, oft en misdiagnosed, with poor symptom-
atic and psychosocial outcome even aft er treatment has 
been initialized, thereby being an important socio-eco-
nomic burden. Although conservative rates of 1–1.6% 
lifetime prevalence were reported in former studies on bi-
polar disorder  [2, 3] , a re-analysis of the US National Ep-
idemiological Catchment Area database found a 6.4% life-
time prevalence for bipolar (spectrum) disorders  [4] . Th is 
increased prevalence was fully accounted for by the inclu-
sion of subthreshold cases: 5.1% lifetime prevalence ver-
sus 1.3% for threshold manic or hypomanic episodes. 
 Most bipolar disorder patients are ‘hidden’: not diag-
nosed at all or falsely diagnosed as suff ering from unipolar 
disorder. In a community survey of Hirschfeld et al.  [5] , 
only 20% of individuals with positive screens for bipolar 
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 Abstract 
 Diagnosis and treatment of bipolar disorder has long been a 
neglected discipline. Recent years have shown an upsurge 
in bipolar research. When compared to major depressive dis-
order, bipolar research still remains limited and more expert 
based than evidence based. In bipolar diagnosis the focus is 
shifting from classic mania to bipolar depression and hypo-
mania. There is a search for bipolar signatures in symptoms 
and course of major depressive episodes. The criteria for hy-
pomania are softened, leading to a bipolar prevalence that 
now equals that of major depressive disorder. Anti-epilep-
tics and atypical antipsychotics have joined lithium in the 
treatment of bipolar disorder. Fortunately, mood stabiliza-
tion has become the core issue in bipolar disorder treatment. 
In contrast with recent trends in the diagnosis of bipolar dis-
order, treatment research remains more focused on classic 
mania than depression or hypomania. This leaves the clini-
cian with the diffi  cult task of diagnosing ‘new bipolar pa-
tients’ for whom no defi nite evidence-based treatment is 
available. An important effi  cacy-eff ectiveness gap further 
compromises the translation of the evidence base on bipolar 
disorder treatment into clinical practice. The recent upsurge 
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disorder had previously received a diagnosis of bipolar 
disorder. Th irty-one percent had been given the diagnosis 
of unipolar depression, whereas 49% had received no such 
diagnosis at all. In this survey the Mood Disorder Ques-
tionnaire was used. It was developed as a screening instru-
ment for bipolar spectrum disorders and has shown a gen-
erally good sensitivity and specifi city with regard to re-
search diagnostic interviews in validation studies, both in 
clinical and non-clinical samples  [6, 7] . Similar results 
were found in a clinical sample of hospitalized bipolar dis-
order patients: 40% of cases were previously misdiag-
nosed as being unipolar  [8] . A period of 7.5  8 9.8 years 
elapsed in this group before a diagnosis of bipolar disor-
der was made. Patients and physicians both seem respon-
sible for this delay in diagnosis and subsequent treatment. 
In a recent survey among members of manic-depressive 
support groups, only 36% of patients had sought help 
within 1 year aft er the onset of symptoms  [9] . Sixty-nine 
percent reported misdiagnoses, with a mean of 3.5 other 
diagnoses and 4 physicians before receiving an accurate 
diagnosis of bipolar disorder. Although healthcare profes-
sionals were mainly blamed for this untimely diagnosis, 
patients substantially underreported their manic (and to 
a lesser extent depressive) symptoms to their care provid-
ers. It is disquieting that these problems of misdiagnosis 
and troubled pathway of care were not signifi cantly diff er-
ent from the results of a similar survey, done 8 years ear-
lier  [10] . 
 Furthermore, bipolar disorder shows a severe and 
chronic course, even aft er treatment has been initialized. 
Symptoms fl uctuate within the full range of aff ective 
symptom severity and polarity. About half of the time, bi-
polar disorder patients are symptomatically ill (syndro-
mal, subsyndromal and minor aff ective symptoms), with 
depressive symptoms predominating over manic, hypo-
manic or mixed symptoms  [11, 12] . Psychosocial out-
come is jeopardized throughout the bipolar spectrum: in-
creased marital disruption, health service utilization, 
need for welfare and disability benefi ts, and suicidal be-
haviour  [13] . Not surprisingly and although very conser-
vative prevalence rates were used for calculation, the 
World Health Organization identifi ed bipolar disorder as 
the fi ft h leading cause of years of life lived with disability 
in the world among people aged 15–44 years  [14] . 
 Th is challenge of bipolar disorder is now answered by 
an upsurge of interest in diagnosis and treatment. New 
diagnostic categories, treatment options and guidelines 
are being developed. Th is paper does not intend to cover 
these developments exhaustively. It rather takes a closer 
look at the origin of this current upsurge of interest. Crit-
ical issues concerning the introduction of the bipolar 
spectrum and mood-stabilizing agents into clinical prac-
tice are discussed. How were these new bipolar disorder 
patients previously diagnosed? Is there such a thing as a 
mood stabilizer? Finally, where does it leave the patient? 
How are these recent developments translated into clini-
cal practice? Although this paper is not a systematic re-
view, extensive Medline searches were performed for the 
various topics. From the papers that were found, refer-
ences were then looked at for other relevant papers. For 
one section in particular, ‘Bipolar disorder – an upswing 
in research’, a more comprehensive and methodological 
Medline search was done, which will be discussed in more 
detail. 
 Bipolar Disorder – An Upswing in Research 
 Research in bipolar disorder is claimed to have been a 
neglected discipline, a ‘scientifi c orphan’  [1, 15] . However, 
in recent years bipolar disorder has received increasing 
attention from clinicians, researchers and society as a 
whole. Th is upsurge of interest is exemplifi ed by the ap-
pearance of the fi rst issue of  Bipolar Disorders (a peer-re-
viewed publication specializing in bipolar disorders) in 
September 1999  [16] , 1999 also being the beginning of the 
publication of all but two of the Medline-cited guidelines 
for treating bipolar disorder in adults (Medline search 
with bipolar disorder as MeSH term, search restricted to 
major topic headings only, practice guideline as publica-
tion type)  [17–27] . 
 In order to have a closer look at these recent changes, 
we performed a bibliometric study focusing on bipolar 
disorder. Research activities in bipolar and depressive dis-
order were compared. Our bibliometric study thereby dif-
fered from an earlier study of Clement et al.  [15] in which 
research activity was looked at in bipolar disorder and 
schizophrenia. Th e search was done using the Medline 
database and covered the last 15 years (1990–2004). Bipo-
lar disorder and depressive disorder were used as MeSH 
terms. By restricting the search to major topic headings 
only, we tried to exclude irrelevant publications as much 
as possible. Th e primary aim was to quantify the publica-
tion activity with regard to bipolar disorder and to com-
pare it with that of depressive disorder. A secondary aim 
was to examine the nature of publication activity by focus-
ing on the type of publications: reviews, clinical trials 
(CT) and randomized controlled trials (RCT). Due to the 
relative selectivity of involved publication types (more di-
rected towards treatment), this further search was made 
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for the subheading ‘drug therapy’ only. Th is selection was 
also in line with the focus of the paper on new pharmaco-
logical treatment options in bipolar disorder. 
 First, a clear upswing of publications on bipolar disor-
der was found, with a marked increase starting in 1999 
( fi g. 1 ). Second and despite this recent increase, there is 
still a dearth of publications on bipolar disorder when 
compared to depressive disorder. However, the ratio (bi-
polar disorder:depressive disorder) is growing ( fi g. 2 ). 
Th ird, bipolar disorder publications on drug therapy are 
characterized by an overrepresentation of reviews versus 
RCT or CT ( table 1 ;  fi g. 3 ). Th e relative numbers of RCT 
and CT versus reviews are diff erent from those seen in 
depressive disorder. Over the study period 1990–2004, the 
ratios CT:review and RCT:review for bipolar disorder 
were 0.77 and 0.38, respectively, versus 1.37 and 0.85 for 
depressive disorder. Even the absolute and recent increase 
in bipolar disorder publications is still more accounted for 
by reviews than by CT or RCT. Th e infl uence of a potential 
overlap in publications between bipolar and depressive 
disorder on these analyses was looked at in subsequent 
and more restricted searches: analysis for depressive dis-
order excluding bipolar disorder and vice versa. Similar 
results (not presented in this paper, but available upon re-
quest) were found. 
 Th e consistency of these fi ndings (diff erential quantity 
and nature of publications) over time and type of search 
method give support for making some tentative conclu-
sions. First, although there is still a dearth of research on 
bipolar disorder when compared to depressive disorder, 
bipolar disorder is catching up with a marked increase at 
the end of the nineties. Th is hinge moment coincides with 
the appearance of the anticonvulsants and atypical anti-
psychotics in the treatment of bipolar disorder. Second, 
publications on drug therapy for bipolar disorder and de-
pressive disorder diff er substantially in the type of publi-
cations. Reviews are overrepresented in bipolar disorder 
when compared to depressive disorder. As to research ac-
tivity on bipolar disorder, this could be interpreted as be-
ing more clinician based or expert based than evidence 
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 Fig. 1. Publication activity in bipolar disor-
der (1990–2004). Medline search, bipolar 
disorder used as MeSH term, search re-
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based. Th is disparity may be explained by the inherent dif-
fi culties of short-term and long-term effi  cacy trials in bi-
polar disorder: high rates of protocol non-completion and 
non-specifi c responses, the extremely labile and rapidly 
changing nature of the condition, the complexity of the 
clinical picture (manic and depressive symptoms are com-
monly intermixed) and the complexity of its treatment 
(combination treatment is more a rule than an exception) 
 [28–30] . Given the limited evidence base, physicians are 
in need of reviews to guide their clinical decisions. 
 Bipolar (Spectrum) Disorder – Extended Diagnosis 
 Past research has focused mainly on bipolar I disorder, 
with mania as its hallmark. Bipolar II disorder (with hy-
pomania), cyclothymia and bipolar disorder not other-
wise specifi ed have been relatively neglected  [31–33] . Th e 
introduction of the bipolar spectrum disorder concept 
has extended these bipolar boundaries  [34–36] . In its 
broadest and dimensional sense, the bipolar spectrum 
may encompass any disorder characterized by unstable 
mood and behaviour, and any recurrent cycling psychiat-
ric disturbance  [37] . 
 A fi rst subset of patients in whom bipolar spectrum 
diagnosis can now be made are patients formerly labelled 
with borderline personality disorder, attention defi cit dis-
order, bulimia nervosa and substance abuse  [37, 38] . 
However, most of the new bipolar disorder patients have 
until now been classifi ed into major depressive disorder 
(MDD), a second and from a clinical point of view most 
important subset. When reviewing the literature, this 
 unipolar-to-bipolar metamorphosis is done in three ways. 
Firstly, there is a search for bipolar signatures in purely 
depressive episodes (major depressive episode, MDE) or 
during the course of MDD. Secondly, the presence of 
broader manic symptoms in MDE (without fulfi lling the 
criteria of a mixed episode as defi ned in DSM-IV) is 
looked at in depressive mixed episode, agitated depres-
sion and depression with anger. Th ese diff erent presenta-
tions of MDE are now given the bipolar label. Th irdly, a 
Table 1. Drug therapy in depressive (DD) and bipolar disorder 
(BD): number and type of publications
1990–1994 1995–1999 2000–2004
DD drug therapy 1,616 1,948 2,450
DD drug therapy review 306 477 546
DD drug therapy CT 515 598 704
DD drug therapy RCT 336 380 417
BD drug therapy 410 601 1,042
BD drug therapy review 77 146 293
BD drug therapy CT 75 100 222
BD drug therapy RCT 45 49 103
Medline search, bipolar disorder and depressive disorder used 
as MeSH terms, search restricted to major topic headings only and 
subheading ‘drug therapy’; CT, RCT and review used as publication 
types.
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greater detection and loosening of the criteria for hypo-
mania have made the bipolar spectrum as prevalent as the 
unipolar spectrum. 
 Depressive Episode – Looking for Bipolar Signatures in 
Course and Symptoms 
 When symptomatically ill, patients with bipolar I and 
II disorder spend most of their time with depressive symp-
toms, more than with manic or hypomanic symptoms: 
31.9 versus 9.3% for bipolar I disorder, and 50.3 versus 
1.3% for bipolar II disorder, respectively  [11, 12] . About 
60% of both groups will experience a depressive episode 
as their fi rst lifetime-aff ective episode  [13] . Furthermore, 
manic symptoms are more oft en underreported to physi-
cians than depressive symptoms  [9] , and current hypo-
manic symptoms, not interfering with normal function-
ing, will not be mentioned at all. Lack of insight, during 
the acute manic episode and even when manic symptoms 
have improved, may be responsible for this underreport-
ing  [39–41] . Th ereby, meeting a bipolar patient is more 
likely during a depressive episode than during a manic or 
hypomanic episode. Th e question then arises which signs 
in course and symptoms may suggest a bipolar origin of 
apparently unipolar disorder patients. Earlier age of onset, 
a greater number of episodes, a relatively acute onset and 
abatement of symptoms are all cited as being indicative of 
bipolar depression  [42, 43] . Although DSM-IV-R criteria 
 [44] assume a common bipolar and unipolar symptom-
atology, recent studies have given proof for symptomatic 
diff erences between unipolar and bipolar depression  [45, 
46] . Mitchell et al.  [45] compared 39 bipolar I with 39 
unipolar disorder patients during a depressive episode. 
No diff erences were found in severity. Bipolar disorder 
patients were more likely to demonstrate a characteristic 
admixture of psychomotor-retarded melancholic and 
atypical depressive features, and to have had more previ-
ous psychotic episodes. Specifi cally, bipolar disorder pa-
tients had more frequent and/or severe symptoms of 
worthlessness, anticipatory anhedonia, subjective rest-
lessness, hypersomnia and leaden paralysis. Objectively 
they showed more psychomotor retardation, but no more 
agitation. Benazzi  [46] compared consecutive unipolar 
and bipolar II depressed outpatients. Besides lower age, 
lower age of onset, longer duration of illness, more recur-
rences, more family history of bipolar II disorder and 
more depressive mixed state, bipolar II disorder patients 
had signifi cantly more atypical features (53 vs. 24%). Fur-
thermore, atypical unipolar and early-onset unipolar dis-
order patients were highly similar to bipolar disorder pa-
tients in terms of age of onset or atypical features, respec-
tively, recurrences, depressive mixed state and family 
history bipolar II disorder. 
 Th e importance of depressive symptoms, course of ill-
ness and response to treatment in diagnosing bipolar dis-
order is taken to a fi nal step by Ghaemi et al.  [47, 48] . A 
defi nition of bipolar spectrum disorder is postulated in 
which (hypo)manic symptoms are no longer required and 
a diagnosis of bipolar disorder can be made solely based 
upon a combination of family history of bipolar disorder, 
hyperthymic personality, and depressive features in symp-
toms and course: recurrent MDE, early age of onset, atyp-
ical features, brief MDE, psychotic MDE, postpartum de-
pression, antidepressant-induced (hypo)mania, antide-
pressant wear-off , lack of response to  6 3 adequate 
antidepressant treatment trials. In a recent study, Ghaemi 
et al.  [49] looked at these ‘bipolar validators’ in consecu-
tively treated bipolar and unipolar disorder patients. Aft er 
adjusting for correlations and interactions between pre-
dictors, the most powerful predictors for bipolar disorder 
were brief MDE, early age of onset, antidepressant-in-
duced mania, postpartum depression and atypical fea-
tures. 
 From Depressive Mixed State to Agitated Depression 
and Depression with Anger 
 Detection of (hypo)manic symptoms in depressive ep-
isodes is a second wave in the unipolar-to-bipolar meta-
morphosis. Mainly, this is done in three ways: the concept 
of depressive mixed states, the re-appraisal of agitated de-
pression and the focus on anger (or irritability) in depres-
sion. 
 Depressive mixed state (DMS) is an MDE accompa-
nied by some manic symptoms, but not fulfi lling the cri-
teria of a mixed episode as defi ned in DSM-IV-R. Its ori-
gin goes back to early classic authors such as Kraepelin 
 [50] , and DMS is now reintroduced as belonging to the 
bipolar spectrum  [51–53] . Sato et al.  [51] reported on the 
frequency of manic symptoms in depressed unipolar and 
bipolar disorder inpatients, and evaluated the validity of 
DMS as bipolar spectrum. Th e frequency of manic symp-
toms (fl ight of idea, logorrhoea, aggression, excessive so-
cial contact, increased drive, irritability, racing thoughts 
and distractability) was signifi cantly higher in depressive 
patients with bipolar I and II than unipolar disorder: 23, 
20 and 9%, respectively. DMS (defi ned as having 2 or more 
of these manic symptoms) had more similarities with bi-
polar than with unipolar depression in clinical variables 
such as family history of bipolar disorder and age at onset. 
In this sample of depressed inpatients, the inclusion of 
depressive mixed state into the bipolar spectrum doubled 
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the ratio bipolar:unipolar, i.e. from 11 to 22%. Benazzi 
and Akiskal  [52] studied the prevalence of DMS in de-
pressed outpatients with MDD and bipolar II disorder. 
DMS with 3 or more hypomanic symptoms (DMS3) was 
found signifi cantly more in patients with bipolar II than 
unipolar disorder: 46.3 versus 7.8%, respectively. Most 
common intra-episode hypomanic symptoms were irrita-
bility, distractability and racing thoughts. A second study 
 [53] confi rmed these earlier results. Furthermore, DSM3 
was signifi cantly associated with variables distinguishing 
bipolar from unipolar disorder: younger age at onset, 
more MDE, more atypical features, and more family his-
tory of bipolar II disorder. 
 Th e issue of agitated depression is extensively covered 
in the infl uential paper of Koukopoulos and Koukopoulos 
 [54] . In their historical review of the concept, the authors 
proposed diagnostic criteria covering various forms of ag-
itated depression: (a) MDE, (b) at least 2 out of 3 symp-
toms (motor agitation, psychic agitation or intense inner 
tension, racing or crowded thoughts). Th e prevalence of 
agitated depression, defi ned as such, was looked at in a 
recent study of Benazzi et al.  [55] . MDE with intense inner 
tension/irritability and racing/crowded thoughts was 
found in 38.6% of depressed outpatients. Other common 
hypomanic symptoms in agitated depression were dis-
tractability and more talkativeness. Th e majority of these 
patients had a diagnosis of bipolar II disorder. Agitated 
depression was strongly and signifi cantly associated with 
external validators for bipolarity (younger age at onset, 
multiple recurrences, family history of bipolar disorder). 
 Anger (anger attacks, persistent anger or irritability) 
has also been linked to bipolar disorder in recent studies. 
Perlis et al.  [56] compared the prevalence and clinical sig-
nifi cance of anger attacks in unipolar versus bipolar de-
pression. Anger attacks were signifi cantly more common 
among depressed patients with bipolar than unipolar-
disorder: 62 and 26%, respectively. Aft er adjusting for 
gender and depression severity, individuals with anger at-
tacks were signifi cantly more likely to have bipolar disor-
der than MDD. A broader defi nition of anger (persistent 
anger, tendency to respond to events with angry out-
bursts) was used in a study of Benazzi  [57] . Th e prevalence 
of anger was looked at in consecutive depressed outpa-
tients (MDD and bipolar II disorder). Th e frequency of 
depressive episodes with anger was 61.2% in bipolar II 
disorder patients and 35.6% in unipolar disorder patients. 
Depression with anger was signifi cantly associated with a 
diagnosis of bipolar II disorder, younger age at onset, 
atypical features, depressive mixed state, and family his-
tory of bipolar disorder. 
 Hypomania – From Hard to Soft  Criteria 
 Hypomania according to DSM-IV-R is defi ned as a 
sometimes short-lasting elevation of mood, identifi ed by 
the usual criteria of mania, but without marked impair-
ment in social or occupational functioning. Th is lack of 
associated impairment makes hypomania a troublesome 
disease state for various reasons  [32] . First, the patient’s 
experience of hypomania is usually ego-syntonic, is not 
associated with signifi cant subjective distress, is some-
times associated with improved functioning and produc-
tivity, and will therefore not be viewed as needing inter-
vention (by either patient or physician)  [58] . Second, di-
agnosing hypomania does not always result in immediate 
treatment of the disease state itself but rather in future 
treatment of the unstable mood and subsequent depres-
sive episodes. Th is apparent paradox has become more 
important as the reported prevalence of bipolar II disor-
der is increasing and almost equals the prevalence of 
MDD. Th is higher prevalence is caused by a better detec-
tion of hypomania, a diff erent use of stem criteria as well 
as a decrease in the number and duration of symptoms 
required for diagnosis. Several of these aspects were 
looked at by Angst et al.  [36] in a 20-year prospective com-
munity cohort study of young adults. Besides formal DSM 
diagnosis, two other concepts of bipolar II disorder were 
considered: (1) MDE with a hypomanic syndrome (hard 
criteria) and (2) MDE with hypomanic symptoms only, 
without consequences (soft  criteria). In order to qualify 
for a strict diagnosis of hypomania (hypomanic syn-
drome), subjects had to: (1) have euphoria, irritability or 
overactivity, (2) have themselves experienced problems or 
received comments from others that something must be 
wrong with them (consequences), (3) present at least 3 out 
of 7 signs and symptoms of DSM-IV hypomania. Th e clin-
ical validity of these concepts was analyzed by family his-
tory, course and clinical characteristics. Overactivity was 
found to be a stem criterion that should be added to eu-
phoric and irritable mood when defi ning hypomania. Ep-
isode length was not withheld as a criterion as long as 3 
out of 7 symptoms were present. Th e two bipolar II sub-
groups (soft  and hard criteria) did not diff er from all but 
one of the validators, whereas they did diff er signifi cantly 
from patients with MDD. Th e combined prevalence of bi-
polar II disorder was 11%. By loosening the criteria of 
hypomania, the ratio depressive disorder:bipolar disorder 
declined from 9.4 to 1.0. Benazzi and Akiskal  [59] , using 
a refi ned defi nition of hypomania, determined the preva-
lence of bipolar II disorder in a selected group of outpa-
tients, presenting spontaneously for treatment of a de-
pressive episode. Th e minimum duration of  6 4 days was 
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not adhered to, and  6 2 days of hypomania was suffi  cient 
for diagnosis. An interview was also done with a modi-
fi ed SCID-CV interview. If the patient’s answer about ‘a 
period of elevated or irritable mood’ was negative, fur-
ther assessment of hypomanic symptoms was not skipped 
(as required by the SCID-CV), but the patient was ques-
tioned about all the other hypomanic symptoms. Th en, 
once an episode of past hypomanic behaviour was re-
membered, patients were re-questioned about ‘a period 
of elevated mood’. Th is approach in depressed outpa-
tients yielded a 61.3% prevalence of bipolar II disorder. 
By modifi cation of the SCID-CV interview, with more 
emphasis on hypomanic behaviour when probing for 
 hypomania, a net gain of 16% was achieved compared to 
a previous study in which a strict SCID-CV was followed 
 [53] . 
 Mood Stabilizers – The Risk of Overpromising and 
Underdelivering 
 Anti-epileptics (divalproex, carbamazepine, lamotrig-
ine) and atypical antipsychotics (aripiprazole, olanzapine, 
quetiapine, risperidone, ziprasidone) have joined lithium 
in the treatment of bipolar disorder. Th e term ‘mood sta-
bilizer’ is now prominently used as a common denomina-
tor for these distinct agents and thereby seems to be the 
therapeutic counterpart of the upsurge in bipolar disorder 
diagnosis. Despite its popularity some critical issues mer-
it further attention. 
 First, the origin of the term is quite recent. For many 
years lithium was the only agent widely used for bipolar 
disorder and thereby synonymous with the concept of 
mood stabilizer and mood stabilization. Th e need for a 
distinct term only came when other agents (divalproex, 
carbamazepine) showed mood-stabilizing properties and 
when it was recognized that some agents used in bipolar 
disorder (e.g. antidepressants and typical neuroleptic 
agents) could worsen the course of the illness  [60–62] . In 
a Medline search of the term ‘mood stabilizer’ (search 
term), only 10 papers are found between 1964 and 1994. 
Th is contrasts sharply with 218 publications in the period 
of 2000–2004 ( fi g. 4 ). 
 Second, although the term ‘mood stabilizer’ is com-
monly used in the marketing of the newer drugs, it is not 
offi  cially recognized by the US Food and Drug Adminis-
tration. Th ere is no real consensus among investigators 
and many defi nitions can be applied  [61, 63–65] . Th e 
most comprehensive defi nition requires (1) effi  cacy in 
acute aff ective symptoms, (2) effi  cacy in psychotic symp-
toms, (3) effi  cacy in behavioural symptoms, (4) effi  cacy in 
cognitive symptoms and (5) effi  cacy in preventing manic, 
mixed and depressive episodes. Ideally, eradication of in-
terepisode subsyndromal symptoms and mood lability 
should also be included. Obviously, this defi nition of a 
magic mood-stabilizing bullet is not met by any of the ex-
isting compounds, and development of such a compound 
does not seem likely. Th e triple option of (1) effi  cacy in 
acute mania, (2) effi  cacy in acute depression and (3) effi  -
cacy in preventing manic and depressive episodes, is a 
more down-to-earth and lithium-inspired defi nition. A 
double option is then (1) effi  cacy in acute mania or acute 
depression and (2) effi  cacy in preventing aff ective epi-
sodes. Another defi nition was proposed by Ghaemi  [61] : 
effi  cacy in 2 of 3 phases of bipolar illness (acute mania, 
acute depression, prophylaxis of mania and depression). 
In the least restrictive and uniphasic way, mood stabilizer 
is defi ned by effi  cacy in at least one phase of the illness 
without exacerbating another phase. All these defi nitions 
disproportionately value the effi  cacy in acute mania or de-
pression, and seem to ignore that treating the longer 
course of the illness is the main issue. In contrast and as 
an answer to this neglect, Harris et al.  [60, 66] have for-
mulated a more radical defi nition of mood stabilizer: 
agents, which show prophylactic effi  cacy, while evidence 
of effi  cacy in the acute phase is not needed. When apply-
ing this defi nition to the evidence base of bipolar disorder 
treatment, as presented in the latest review of Bauer and 
Mitchner  [63] , only lithium and to a lesser extent la-
motrigine are really mood stabilizers. 
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 Fig. 4. Publication activity regarding ‘mood stabilizer’ between 
1964 and 2004. Medline search, ‘mood stabilizer’ as search term. 
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 Th ird, none of the new agents has been specifi cally de-
signed for mood-stabilizing purposes. Th ey are distinct 
products and most have a primarily proven antipsychotic 
or anti-epileptic eff ect. Th eir mood-stabilizing properties 
have only been shown secondarily: fi rst in bipolar mania 
or depression, second in prophylactic treatment. New no-
menclatures (mood stabilizer, mood stabilizers from be-
low, mood stabilizers from above) could then be seen as 
artifi ces  [67] . Diff erent mechanisms of action are being 
covered up by a common denominator. Furthermore, re-
search should look for functional diff erences between 
these distinct agents. Functional diff erences, based upon 
diff erent mechanisms of action, may be overlooked when 
they are evaluated by the broad category of mood stabili-
zation. 
 Fourth, mood stabilizer is a popular and easy-to-sell 
concept, but fails to describe the diffi  cult clinical task of 
treating bipolar disorder patients. In this chronic and cy-
clic disease, the clinician is faced with the ongoing chal-
lenge of keeping the patient symptom free and preventing 
the aff ective pendulum from swinging too far toward ma-
nia or depression  [68] . For many patients mood stabiliza-
tion is only achieved with the combination of drugs: a 
cocktail of drugs with some mood/psycho-stabilizing 
properties instead of a unique mood stabilizer  [69–71] . 
 Mood Stabilizers and Bipolar (Spectrum) Disorder – 
What Is in It for the Patient? 
 Translation into clinical practice should be the ultimate 
issue in this upsurge of research, diagnosis and treatment 
of bipolar disorder. Multiple caveats should here be men-
tioned: these concern both bipolar disorder in general and 
bipolar spectrum disorder more specifi cally. 
 Th e limited evidence base of bipolar disorder is under-
mined by an important effi  cacy-eff ectiveness gap. Many 
factors contribute to this disparity between the perfor-
mance of an intervention in the controlled environment 
of an experimental study and its performance in clinical 
practice  [72] . First, due to enrolment practices (e.g. selec-
tion of patients that can provide informed consent and are 
able to comply with study requirements), less severely ill 
patients are recruited. Th is could explain the high placebo 
responses seen in recent trials for acute mania  [73] . Dur-
ing a 4-week, randomized, double-blind, parallel study, 
olanzapine demonstrated signifi cantly greater effi  cacy 
than placebo in the treatment of acute bipolar mania  [74] . 
However, response (defi ned as at least a 50% improve-
ment from baseline to endpoint in the Young Mania Rat-
ing Scale, Y-MRS) was as high as 43% in placebo-treated 
patients (versus 65% in olanzapine-treated patients). Sec-
ond, concomitant medication (apart from study medica-
tion and benzodiazepines) is prohibited in most studies, 
and controlled combination studies in bipolar disorder 
are uncommon  [75] . Th is contrasts sharply with clinical 
practice in which combination treatment is more a rule 
than an exception. Th ird, the primary effi  cacy measures 
of most short-term clinical trials present a far too optimis-
tic view of improvement, not seen in clinical practice. Ef-
fi cacy is oft en measured as a mean change in rating scale 
score, or the proportion of patients showing a 50% or 
greater decrease in initial score. Many of these ‘respond-
ers’ remain signifi cantly ill, and will need more time or 
combination treatment for complete symptomatic recov-
ery. Th e magnitude of this problem was shown by Chen-
gappa et al.  [76] , in a re-analysis of the results of two short-
term, randomized, double-blind trials of olanzapine ver-
sus placebo for treating acute bipolar mania. Various 
effi  cacy measures were used: response ( 6 50% decrease 
from baseline to endpoint in total Y-MRS score), euthymia 
(an endpoint Y-MRS score  ^  12) and remission (an end-
point total Y-MRS score  ^  7, an endpoint total Hamilton 
Depression Rating Scale score  ^  7, and an endpoint Clin-
ical Global Impression Scale – Bipolar Version overall se-
verity score  ^  2). Th e rates of response, euthymia and re-
mission of olanzapine versus placebo were: 55 versus 
29.5%, 50 versus 27%, and 18 versus 7%, respectively. Due 
to its short duration, this analysis could not assess the 
problem of sustained improvement and functional recov-
ery: how many of the remitted patients remain in remis-
sion during a longer follow-up, and how many patients 
return to their baseline functional status? Th e importance 
of these phenomena in the clinical course of bipolar illness 
has recently been described by Tohen et al.  [77] who fol-
lowed 166 bipolar patients 2–4 years aft er their fi rst hos-
pitalization (for a manic or mixed episode). Although all 
but 2% of the patients experienced syndromal recovery, 
28% remained symptomatic (Y-MRS score  1 5 or Hamil-
ton Depression Rating Scale Score  1 8), 57% did not 
achieve functional recovery, and 57% switched or had a 
new illness episode. 
 Th ere is a huge disparity between the current develop-
ment of new diagnostics, with special consideration of bi-
polar depression and hypomania, and research that still 
focuses on the treatment of classic mania and bipolar I 
disorder. In bipolar I or II disorder the ratio of time spent 
with depressive versus manic symptoms is 3.4 and 38.7, 
respectively  [11, 12] . However, bipolar depression re-
mains understudied. In the review of Bauer and Mitchner 
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 [63] , 48 class A trials examining the effi  cacy of agents in 
the treatment of acute manic symptoms in bipolar disor-
der were found, including 2,352 patients. For the treat-
ment of acute depressive symptoms only 16 trials were 
withheld, including 637 patients. Th is leads to a ratio de-
pression versus mania of 1:  3 (for class A trials) and 1:  4 (for 
the number of studied patients). 
 Although atypical features, early age at onset, depres-
sive mixed state, agitated depression and depression with 
anger are found to belong to the bipolar spectrum, treat-
ment implications are less clear. Th ere is no consensus that 
these features are predictive of poor outcome during acute 
treatment with antidepressants  [78] , and research on the 
use of mood stabilizers (like lamotrigine or atypical anti-
psychotics) in this soft  bipolar spectrum is just starting. 
In light of the great bipolar II prevalence  [33] , the lack of 
research on bipolar II disorder is even more problematic 
 [79] . 
 Discussion 
 Bipolar disorder is no longer a neglected discipline or 
scientifi c orphan. Th ere is a marked upswing of research, 
refl ected in increased publication activity. When com-
pared with depressive disorder, this publication activity is 
still limited. Publications on drug treatment are more cli-
nician based or expert based than evidence based. Opin-
ion leaders and experts have the important and diffi  cult 
task of translating the evidence-based effi  cacy into clinical 
eff ectiveness and to answer questions for which no evi-
dence-based answers exist. However, this also puts bipolar 
disorder at risk of being too infl uenced by experts and 
opinions. Oft en reviews will not diff er in the evidence that 
is reviewed, but in the story that connects the evidence, 
the story or opinion thereby being more important than 
the facts. An example of this latter phenomenon is the 
current controversy surrounding the treatment of bipolar 
depression, with European and American experts plead-
ing for or cautioning against the use of antidepressants 
 [80, 81] , leaving clinicians with too many choices and per-
haps the false postmodern impression that no choice is 
worthwhile to choose for. Th is makes bipolar disorder 
even more vulnerable to publication bias, pharmaceutical 
propaganda or disease mongering  [82, 83] . 
 Diagnosis of bipolar disorder has made a shift  from 
mania towards depression and hypomania. Features of the 
course and symptoms in depressed patients are found to 
be indicative of a bipolar origin: admixture of psychomo-
tor-retarded melancholic and atypical features, atypical 
features, early age of onset, brief MDE, antidepressant-in-
duced mania, post-partum depression. Manic symptoms 
are now looked at in depression. Th is gives rise to a re-
newed interest in agitated depression, depressive mixed 
states and depression with anger/irritability: distinct but 
also overlapping depressive presentations that are now 
given a bipolar label. Criteria for hypomania are changing, 
with a diff erent use of stem criteria and a decrease in the 
number and duration of symptoms. All these changes lead 
to a dramatic increase in the prevalence of bipolar (spec-
trum) disorder that now equals that of unipolar disorder. 
Th e complexity of a diagnosis of bipolar disorder should 
be welcomed aft er the simplicity of the antidepressant era, 
in which a pharmacocentric view had levelled all diagnos-
tic and therapeutic subtleties. Th is complexity is further 
in line with that of clinical practice: the diffi  culty of treat-
ing a patient with serious aff ective illness. Furthermore, 
this complexity is not new and goes back to historical au-
thors like Griesinger, Kraepelin and Weygandt  [84, 85] . 
Limitations of this extended-spectrum diagnosis seem 
twofold. First, increasingly broad defi nitions could trivial-
ize the core concept of bipolar disorder  [86] . By using a 
spectrum approach, bipolar disorder carries the risk of 
replacing an antidepressant view of the world by a bipolar 
one. It may be hoped that current fi ndings of bipolar sig-
natures in depression, depressive mixed states and hypo-
mania will be replicated in further studies and then inte-
grated in the offi  cial diagnostic systems. Second, besides 
diagnostic validity there is the question of diagnostic util-
ity. Although the bipolar validity of depressive mixed 
states and agitated depression has been shown, the utility 
of these concepts (i.e. short-term and long-term eff ective-
ness of mood-stabilizing agents in these conditions) needs 
further proof. Confronted with these new bipolar pa-
tients, clinicians are now dealing with too many uncer-
tainties. First, there is the uncertainty or probability of the 
diagnosis of bipolar disorder. Second, there is the uncer-
tainty of the subsequent treatment (for bipolar disorder in 
general and bipolar spectrum disorder specifi cally less ev-
idence-based and more expert-oriented). As with diagno-
sis, it may be hoped that further studies will take a closer 
look at the eff ectiveness of known bipolar disorder treat-
ments in these new bipolar states. 
 Various mood stabilizers, besides lithium, have ex-
panded the bipolar armamentarium. Mood stabilization 
is increasingly recognized as the cornerstone of bipolar 
treatment. Th is should be applauded in view of the over-
use of antidepressants, with the risk of induction of mania, 
cycle acceleration and treatment failure. Despite its popu-
larity, the term ‘mood stabilizer’ should not be used loose-
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ly, as it could help to order priorities for bipolar treatment 
 [62] . Prevention of future episodes should be the primor-
dial feature of a mood-stabilizing drug  [60] . Other prop-
erties (e.g. eff ectiveness in acute mania or depression) are 
secondary assets. Besides prophylactic treatment, re-
search should focus more on bipolar depression, being 
more common than mania and less studied. Furthermore, 
mood stabilizers are all very distinct agents. Not only 
must their common mood-stabilizing properties be 
looked at, but also possible drug-specifi c psychotropic ac-
tions  [87] . 
 Finally and building upon the former conclusions, fur-
ther research on bipolar disorder treatment has to close 
the gap between the limited evidence of effi  cacy trials, the 
opinions of experts and the experience of clinicians. 
Large-scale, randomized, controlled trials are needed, in-
cluding a heterogeneous group of patients, not excluding 
the severely ill and rapidly recurrent subgroups, compar-
ing several putative mood-stabilizing agents (one treat-
ment or in combination), assessing an outcome of direct 
clinical importance and being designed in a way that 
makes them user friendly for clinicians  [29, 30, 88, 89] . 
Trials that fulfi ll these requirements are diffi  cult to install 
and are counter to the approach of most industry-funded 
effi  cacy trials (recruiting a homogeneous sample of pa-
tients and using primary outcomes of uncertain clinical 
meaning), designed for regulatory purposes. BALANCE 
(bipolar aff ective disorder: lithium/anticonvulsant evalu-
ation), funded by the Stanley Foundation, is an example 
of how such trials can be installed. Aft er a run-in phase, 
during which they receive a combination of lithium and 
valproate for up to 8 weeks, patients will be randomized 
to receive lithium/valproate as monotherapy or combina-
tion treatment, and will be followed up for 2 years  [90, 91] . 
Th e trial is open to any patient with bipolar disorder who 
agrees to commence maintenance treatment, but faces 
clinical uncertainty about the optimal treatment. Primary 
outcome is the time to hospital admission. Healthcare 
agencies are probably the best placed to carry out these 
eff ectiveness studies. Unfortunately, their funding for re-
search on bipolar disorder has been markedly low in the 
past. In two papers of Torrey et al.  [92, 93] , research grants 
funded by the National Institute of Mental Health were 
analysed. In 1997 and 1999, research grants for bipolar 
disorder accounted for only 3.5 and 2.4% of the total 
grants, respectively. Th ese percentages were substantially 
lower than those for depressive disorder and schizophre-
nia: 13.8 and 8.9% for depressive disorder, 11.6 and 8.2% 
for schizophrenia. It may be hoped that the initiation of 
the National Institute of Mental Health Systematic Treat-
ment Enhancement Program for Bipolar Disorder (STEP-
BD), examining the longitudinal course of the illness and 
the eff ectiveness of current treatments, is a new trend and 
that similar research on bipolar disorder will be continued 
in the future  [94, 95] . 
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